Bloomberg Markets & Finance via Youtube

Aug.26 — Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co. Bloomberg’s Kailey Leinz reports on “Balance of Power.”

READ ALSO  US Elections: The Risk Of Copying Europe